Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults

NCT04750343 is registered in ClinicalTrials.gov with SK Bioscience Co., Ltd. as lead sponsor.

NCT NCT04750343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04750343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults
Lead sponsor
SK Bioscience Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 3, 2021
Completion date
June 30, 2022
Enrollment
328 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 (healthy volunteers)